Current treatment of HIV infection

The treatment of HIV infection in the industrialised countries has undergone manifest changes during the past decade. Since the advent of zidovudine in 1987, the first agent capable of delaying disease progression, several other nucleoside analogues have been introduced, though in retrospect the effect of these drugs can now be seen to have been moderate. With the introduction of proteinase inhibitors, more effective control of infection became possible, and the combination of a proteinase inhibitor with two nucleoside analogues yielded a triple-drug treatment capable of halting progression for a large proportion of patients. Thus, during recent years the disease course has changed in character from successive deterioration of the immune defence system to a condition where most patients can live virtually normal lives in many respects. For some patients, however, the new drugs have been associated with side effects, and our knowledge of the long-term effects is still insufficient.     

Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function

OBJECTIVES: To determine whether highly active antiretroviral therapy (HAART) is associated with reduced HIV-associated neuropsychological impairment. DESIGN: Cross-sectional analysis in a natural history study of adaptation to HIV/AIDS. METHOD: A sample of 130 homo-/bisexual men with HIV/AIDS (mean age, 41 years; 42% non-white) were evaluated with a neuropsychological battery assessing attention, concentration, psychomotor speed, learning, memory and executive function. Subjects taking HAART were compared with those not taking HAART on demographics, CD4 cell count, viral load, scores on individual neuropsychological tests and proportion with neuropsychological impairment. RESULTS: Sixty-nine (53%) subjects were taking HAART, and 48 (37%) were neuropsychologically impaired. Subjects taking HAART had lower mean CD4 cell counts than those not taking HAART (254 versus 342 x 10(6)/l; P < 0.05), although they were more likely to have undetectable viral load (42 versus 20%; P < 0.01) and were less likely to be neuropsychologically impaired (22 versus 54%; P < 0.0001). Subjects taking HAART performed significantly better on tests of attention, concentration, learning, memory, and psychomotor speed. After excluding subjects with potential non-HIV confounders of neuropsychological function, those without neuropsychological impairment had significantly lower mean viral load levels and were more likely to have undetectable viral load than those with impairment. CONCLUSION: These preliminary findings suggest that HAART benefits neuropsychological function through the reduction of viral load.     

An aggressive approach to HIV antiretroviral therapy

The introduction of highly active antiretroviral therapy offers the first real hope of durable control of HIV infection and prevention of clinical sequelae. But success hinges on early and complete suppression of viral replication. That demands near-perfect adherence to a complex regimen involving three or more drugs, each with its own dosage and dietary requirements.     

Use of combination antiretroviral therapy in pregnant women with HIV disease

Important advances in human immunodeficiency virus (HIV) medicine have brought about numerous changes in the clinical care of HIV-infected individuals. The availability of protease inhibitors to treat HIV infection, the introduction of HIV-RNA polymerase chain reaction viral load tests to monitor responses to therapy, and the greater clinical benefit offered by combination highly active antiretroviral therapy (HAART) over monotherapy have dramatically decreased morbidity and mortality rates. The safety and efficacy of HAART has not been proved in pregnant women with HIV, although withholding HAART in HIV-infected women because of pregnancy is not recommended. This article presents an overview of important clinical issues relevant to the use of combination antiretroviral therapy in pregnancy.     

Effect of antiretroviral treatment on early electroencephalographic and otoneurologic manifestations in HIV infection and prognostic importance of verified perturbations

Electrophysiologic tests may be abnormal in asymptomatic HIV-1-infected individuals. Our study was aimed at determining whether these findings have a prognostic value and could be corrected by antiviral treatment. In 18 patients, followed for 34 or 43 months, these findings were not progressive. Only one patient developed Aids dementia complex (ADC). Three have died (one with normal, two with abnormal tests at baseline). To study the effect of antiviral treatment, another group of seven asymptomatic patients was included into a cross-over double-blind study with either eight weeks zidovudine or eight weeks placebo, separated by eight more weeks without treatment. Electrophysiological evaluation was also performed in a group of 15 patients before antiviral therapy with zidovudine or didanosine was started and again after a mean of three and 13 months treatment. Results did not suggest that treatment reverses early electroencephalographic and otoneurological changes seen in HIV-1 infection.     

Current status of HIV infection in Yunnan Province of China

In cooperation with the Chinese Academy of Preventive Medicine and Yunnan Province Provincial Office for AIDS Control and Prevention, we studied the current status of HIV infection intravenous drug users (IVDUs) and other high risk groups in Yunnan province of China. As of the end of 1995, 1,807 HIV cases were officially reported (Positive rate was 0.6%), of which 1,278 (77.9%) were IVDUs, and 24 were their spouses. The majority of cases were found among the Dai minority male farmers near Ruili which borders on Myammar, but HIV also appears to be spreading among the Han people. HIV antibody positive rates among commercial sex workers, pregnant women and blood donors were 0.2%, 0.07% and 0.04%, respectively. A system for surveillance of HIV has been developed, but preventive strategies to cope with HIV epidemic are not sufficient. As HIV/AIDS is now a global issue, (1) the integration and coordination of such preventive strategies in cooperation with community health workers, (2) general health education for condom use promotion and (3) care of psychological vulnerable person such as IVDUs, should be developed.